Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic and Affy Amend Terms of Microarray Supply Agreement; Subscription Payment to Affy Slashed

NEW YORK, Dec. 30 (GenomeWeb News) - Gene Logic yesterday announced amendments to its 2002 microarray supply agreement with Affymetrix.

 

In an SEC filing, Gene Logic said that it will pay Affymetrix a mere $500,000 in annual subscription fees in 2005, instead of $4 million that it paid in prior years.

 

Gene Logic also said it will purchase at least $500,000 worth of Affymetrix products and services this month, and at least another $9.5 million in 2005.

 

The companies will also establish pricing for probe array products for the period between July 1, 2003 and Dec. 31, 2005.

 

The original contract, effective since Jan. 1, 2002, sets the terms for supplying Gene Logic and its subsidiaries with DNA probe arrays from Affymetrix for developing database products and services. That agreement, disclosed in a 2002 SEC filing by Gene Logic, did not provide any financial details.

 

The two companies first announced a supply agreement in January of 1999, which the 2002 agreement replaced.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.